Comment on

• Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.

  Giannopoulos A, Manousakas T, Gounari A, Constantinides C, Choremi-Papadopoulou H, Dimopoulos C. Giannopoulos A, et al. J Urol. 2001 Aug;166(2):470-5. J Urol. 2001. PMID: 11458049
• Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer.

  Kielb SJ, Shah NL, Rubin MA, Sanda MG. Kielb SJ, et al. J Urol. 2001 Aug;166(2):482-7. J Urol. 2001. PMID: 11458051